ReviewJournal of hepatocellular carcinoma2016

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.

Jörg Trojan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.